Next Article in Journal
Cadmium Protection Strategies—A Hidden Trade-Off?
Next Article in Special Issue
Argonaute and Argonaute-Bound Small RNAs in Stem Cells
Previous Article in Journal
Elucidating the Diversity of Aquatic Microdochium and Trichoderma Species and Their Activity against the Fish Pathogen Saprolegnia diclina
Previous Article in Special Issue
Pluripotency Genes and Their Functions in the Normal and Aberrant Breast and Brain
Article Menu
Issue 1 (January) cover image

Export Article

Open AccessReview
Int. J. Mol. Sci. 2016, 17(1), 141; doi:10.3390/ijms17010141

An Overview of Direct Somatic Reprogramming: The Ins and Outs of iPSCs

1
Hagey Laboratory for Pediatric Regenerative Medicine, Department of Surgery, School of Medicine, Stanford University, 257 Campus Drive, Stanford, CA 94305, USA
2
Dipartimento di Scienze Biomediche Avanzate, Universita’ degli Studi di Napoli Federico II, Napoli 80131, Italy
3
Institute for Stem Cell Biology and Regenerative Medicine, School of Medicine, Stanford University, Stanford, CA 94305, USA
*
Authors to whom correspondence should be addressed.
Academic Editor: Wenbin Deng
Received: 15 December 2015 / Revised: 12 January 2016 / Accepted: 13 January 2016 / Published: 21 January 2016
View Full-Text   |   Download PDF [1126 KB, uploaded 21 January 2016]   |  

Abstract

Stem cells are classified into embryonic stem cells and adult stem cells. An evolving alternative to conventional stem cell therapies is induced pluripotent stem cells (iPSCs), which have a multi-lineage potential comparable to conventionally acquired embryonic stem cells with the additional benefits of being less immunoreactive and avoiding many of the ethical concerns raised with the use of embryonic material. The ability to generate iPSCs from somatic cells provides tremendous promise for regenerative medicine. The breakthrough of iPSCs has raised the possibility that patient-specific iPSCs can provide autologous cells for cell therapy without the concern for immune rejection. iPSCs are also relevant tools for modeling human diseases and drugs screening. However, there are still several hurdles to overcome before iPSCs can be used for translational purposes. Here, we review the recent advances in somatic reprogramming and the challenges that must be overcome to move this strategy closer to clinical application. View Full-Text
Keywords: embryonic stem cells; adult stem; somatic reprogramming; induced pluripotent stem cells (iPSCs) embryonic stem cells; adult stem; somatic reprogramming; induced pluripotent stem cells (iPSCs)
Figures

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Menon, S.; Shailendra, S.; Renda, A.; Longaker, M.; Quarto, N. An Overview of Direct Somatic Reprogramming: The Ins and Outs of iPSCs. Int. J. Mol. Sci. 2016, 17, 141.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top